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Background: Knee osteoarthritis is a major cause of disability in the aging population. Based on pathological,
magnetic resonance imaging (MRI) and arthroscopy studies, progressive osteoarthritis involves all tissues of the joint
and includes bone marrow lesions, synovial proliferation, fat pad inflammation, and high subchondral bone
turnover. Recent research suggests that abnormal perfusion in bone marrow lesions, fat pads, and subchondral
bone is associated with pain in knee osteoarthritis, and that dynamic contrast-enhanced MRI is a promising method
for studying micro-perfusion alteration in knee osteoarthritis. Traditional Chinese Medicine approaches have been
employed for thousands of years to relieve knee osteoarthritis pain. Among herbal medicines, the Jingui external
lotion is the preferred and most commonly used method in China to reduce pain in patients with knee osteoarthritis;
however, there is a lack of validated evidence for its effectiveness. The purpose of this study is to explore the
effectiveness of Jingui external lotion for the management of painful knee osteoarthritis in a short-term study.
In addition, we will assess micro-perfusion alteration in the patellar fat pad as well as the femur and tibia
subchondral bone via dynamic contrast-enhanced MRI.
Methods/design: This trial is a randomized, controlled study. A total of 168 patients will be randomized into the
following two groups: 1) the Jingui external lotion group (treatment group); and 2) the placebo lotion group (control
group). In both groups, lotion fumigation and external washing of the patients’ knees will be administered twice a
day for 14 consecutive days. Follow-up will be at regular intervals during a 4-week period with a visual analog scale
to assess pain, and additional characterization with the Western Ontario and McMaster Universities Index score;
rescue medication will be recorded as the extent and time pattern. In addition, micro-perfusion alteration in
the patellar fat pad, femur and tibia subchondral bone will be assessed via dynamic contrast-enhanced MRI.
Discussion: This study will provide clinical evidence of the efficacy of Jingui external lotion in treating knee
osteoarthritis, and it will be the first randomized controlled trial to investigate micro-perfusion alteration of knee
osteoarthritis with Traditional Chinese Medicine external lotion via dynamic contrast-enhanced MRI.
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Knee osteoarthritis (KOA) is a major cause of disability
in the aging population and a burden on healthcare
resources [1,2]. The risk of disability (defined as needing
help walking or climbing stairs) attributable to KOA is
as great as that attributable to cardiovascular disease
and greater than that due to any other medical condition
in elderly persons [3]. Pathologically, osteoarthritis (OA)
is characterized by progressive loss of articular cartilage
and new bone formation on conventional radiography.
However, it is increasingly apparent, based on patho-
logical, magnetic resonance imaging (MRI) and arth-
roscopy studies, that progressive OA involves all joint
tissues including bone marrow lesions, synovial prolifer-
ation, fat pad inflammation, and high subchondral bone
turnover [4-7]. This progressive joint failure causes pain,
physical disability, and psychological distress, although
many with structural and radiological changes consistent
with OA are asymptomatic [8]. In recent years, more
attention has been placed on micro-perfusion alteration
in KOA. Studies [9-11] employed dynamic contrast-
enhanced (DCE) MRI to investigate the association be-
tween knee pain and periarticular perfusion variables.
These results suggest that abnormal perfusion including
bone marrow lesions, fat pad, and subchondral bone as
detected by DCE MRI are associated with pain in KOA
and that DCE MRI is a promising method for studying
micro-perfusion alteration in KOA.
The aim of KOA treatment is to reduce pain, im-
prove physical function, prevent disability, and enhance
the quality of life over the short term. Therefore, as
aging and comorbidities increase, a more convenient
approach is urgently needed. In China, and increas-
ingly worldwide, pharmacological therapy guidelines
recommend topical medications as an alternative, ad-
junctive therapy, or even first-line therapy for KOA
[12,13]. Before oral administration, topical treatments
are usually recommended to relieve mild or moderate
KOA pain because of their favorable safety profiles. To
relieve KOA pain, herbal external therapy, including
plasters, ointments, and lotions, have been used under
the principle of syndrome differentiation based on
Traditional Chinese Medicine (TCM) theory for thou-
sands of years. External plasters have been reported to
be very important therapies that induce muscle relax-
ation and invigorate blood circulation [14,15]. Jingui
external lotion with fumigation and washing therapy
has been employed as an effective prescription to
relieve KOA pain or joint stiffness over decades, but
no randomized controlled trial evidence has been pub-
lished. Published Chinese literature has documented
that Jingui external lotion is efficacious in treating
KOA; however, these interventions have not been
rigorously evaluated, and have been regarded to beless credible due to a lack of objective evidence.
Therefore, we designed a randomized, single-blind,
placebo-controlled trial to explore the effectiveness of
Jingui external lotion for the management of painful
KOA in a short-term study and the micro-perfusion
alteration in the patellar fat pad, femur and tibia sub-
chondral bone via DCE MRI.
Methods/design
Study design
This is a randomized, double-blind, placebo-controlled
trial. The trial protocol has been approved by the
Research Ethical Committee of Guangdong Provincial
Hospital of TCM, (reference B2014-001-01). The trial
will be conducted in accordance with the Helsinki
Declaration and will be monitored by the trial agency at
Guangdong Provincial Hospital of TCM.
Recruitment and consent
KOA patients scheduled for conservative treatment at the
Outpatient Department of Orthopedic Surgery, Guang
Dong Provincial Hospital of TCM, will be recruited,
with a target sample size of 168 subjects. All candi-
dates will go through a standardized interview process
and receive more information about the study and the
treatments. Written consents will be obtained. The
purpose, procedures, and potential risks and benefits
of the study will also be explained thoroughly to the
participants. The more painful knee will be chosen as
the study knee, and if both knees have the same
symptoms we will choose the right side. The partici-
pants will be able to withdraw from the study at any
time without consequence. The trial will be executed
from March 2014 to March 2016 including enrollment
and follow-up (Figure 1).
Inclusion criteria
Participants meeting the following criteria will be
included:
 Meet the diagnostic criteria for KOA (American
College of Rheumatology criteria [16])
 Aged from 50 to 80 years old
 Symptomatic KOA with pain of at least 20 mm on a
100-mm visual analogue scale (VAS)
 Grade 0 to 3 on The Kellgren-Lawrence grading
system
 No serious medical history or severe vascular lesions
on lower limbs
 No known drug allergies, including to the contrast
agent, and no MRI contraindications
 Willingness to give written informed consent and
willingness to participate in and comply with the
study.
4 weeks outcome assessment: 
VAS score, WOMAC score, rescue 
medication
4 weeks outcome assessment: 
VAS score, WOMAC score, rescue 
medication 
2 weeks outcome assessment: 
VAS score, WOMAC score, rescue 
medication, DCE-MRI parameters, safety 
assessments 
2 weeks outcome assessment: 
VAS score, WOMAC score, rescue 
medication, DCE-MRI parameters, safety 
assessments 
Included : 
• Meet the diagnostic criteria for knee osteoarthritis; aged from 50 ~ 80 years old; • Symptomatic knee 
OA with a pain of at least 20 mm on a 100-mm VAS; • The Kellgren-Lawrence grading system shown 
rade 0-3; • Without serious medical history, without any severe vascular lesions on lower limbs; • 
Without any study drug allergy, including contrast agent, no MRI contraindications; • Willingness to 
give written informed consent and willingness to participate in and comply with the study. 
Excluded: 
•  Have MRI contraindications,study 
drug allergy; • None degenerative 
osteoarthritis, such as rheumatoid 
arthritis, gouty arthritis, infectious 
arthritis, charcot arthritis, etc; • Can't 
stop using painkillers; • Failed to obtain 
informed consent 
1 week outcome assessment: 
VAS score, WOMAC score, rescue 
medication 
Allocated to Jingui external 
lotion group (n=84 ) 
Allocated to placebo lotion 




Baseline Assessment:   





1 week outcome assessment: 
VAS score, WOMAC score, rescue 
medication
Follow-Up 
Figure 1 Study flow chart. DCE MRI, dynamic contrast-enhanced magnetic resonance imaging; OA, osteoarthritis; VAS, visual analogue scale;
WOMAC, Western Ontario and McMaster Universities Index.
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Participants meeting one or more of the following cri-
teria will be excluded:
 MRI contraindications, or study drug allergy
 Non-degenerative OA, such as rheumatoid arthritis,
gouty arthritis, infectious arthritis, Charcot arthritis,
and so forth Unable to discontinue use of painkillers
 Unwilling to give informed consent.Interventions
Eligible patients will be randomized into the following
two groups: the Jingui external lotion group (treatment
group) and the placebo lotion group (control group).
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fumigating and washing externally for 2 weeks on both
knees. DCE MRI examination will be performed at base-
line and 2 weeks after the intervention is completed.
The participants will be given personal instructions for
using the lotions by our research nurses, who will be
trained before the study. Patient visits will be performed
at baseline and at 1, 2, and 4 weeks after treatment.
Assessments including the VAS score for pain, Western
Ontario and McMaster Universities Index (WOMAC)
score and complications will be made during all four
visits on the study knee.
The treatment group will receive Jingui external lotion,
to be used twice a day (morning and evening, approxi-
mately every 12 hours and at the same time each day)
for 14 consecutive days. The Jingui external lotion will
be made according to the following procedure: a mixture
of TCM (composed of Semiliquidambar cathayensis
60 g, Radix zanthoxyli 60 g, Radix aconiti kusenzoffii
30 g, Radix aconite 30 g, Tinospora sinensis merr 30 g,
Erythrina indica lam 30 g, Rheum officinale 30 g, Cassia
twig 30 g) will be boiled in 300 ml water, reduced to
150 ml of liquid medicine, and cooled to approximately
40°C. These hot liquid medicines will be administered as
Jingui external lotion to the patients’ knees.
The control group will receive placebo lotion contain-
ing a food coloring agent and a small amount of Rheum
officinale that is identical to the treatment group in
terms of color and odor. The manufacturing and treating
procedure are the same as the treatment group.
The research nurses will be involved in the treatment
procedure to ensure the correct treatment is adminis-
tered and that the temperature of the lotions is tolerable
to the patients. During the process, when patients ex-
perience moderate pain or VAS score over 30 mm, ibu-
profen sustained-release capsules will be administrated
as rescue medication. Rescue medication consumption
and time will be recorded in each randomized group
when used. The patients will not be allowed to use other
drugs aimed at treating KOA.
Dynamic contrast-enhanced magnetic resonance imaging
examination
The subjects will receive DCE MRI on the study knee at
baseline and 2 weeks after intervention using a 3.0 T scan-
ner (Magnetom Tim Trio; Siemens Medical Solutions,
Erlangen, Germany) with an eight-channel transmit-
receive phased array knee coil (In vivo Corporation,
Gainesville, FL, USA). The knee imaging protocol will
consist of a sagittal three-dimensional high-resolution T1-
weighted fast low angle shot sequence with selective water
excitation (TR/TE = 500/20 ms; flip angle = 25; FOV =
18.0 cm; slice thickness = 3 mm; matrix = 320 × 240;
receiver bandwidth = 200 Hz/pixel) as well as a sagittalT2-weighted fat-saturated spin echo (TR/TE = 4790/
84 ms; FOV = 18.0 cm; slice thickness = 3 mm; matrix =
320 × 240; receiver bandwidth = 130 Hz/pixel). The syn-
ovial membrane will be evaluated using DCE sagittal
three-dimensional T1-weighted fast low angle shot se-
quence with the following parameters: TR/TE = 12/3.9 ms,
flip angle = 60; FOV = 15 × 15 cm, slice thickness = 5 mm,
matrix = 256 × 128, receiver bandwidth = 200 Hz/pixel,
temporal resolution = 30 seconds. This sequence will be
acquired in contiguous 5-mm sagittal slices throughout
the knee before, during and after intravenous bolus admin-
istration of double-dose contrast agent gadolinium diethyl-
ene triamine pentaacetic acid (0.2 mg/kg). Baseline pre-
contrast static images as well as DCE images will be
acquired after bolus injection [17,18]. The total acquisition
time for the imaging protocol is 24 minutes.
Three-dimensional images of the knee joint will be
rebuilt using a Leonardo workstation (Siemens Med-
ical Solutions INC USA, 2501 North Barrington Rd,
Hoffman Estates Il 60195). The sagittal DCE sequence
images and the intensity-time curve will be attained
with the mean curve function. Four similar subchon-
dral rectangular regions of interest (pixel area of 30)
will be selected in the medial and lateral compartment
of the distal femur and tibia plateau as well as the
infra-patellar fat pad and supra-patellar fat pad. Meas-
urement of these regions will be performed in terms
of the enhanced rate and maximum upslope.
Outcome measures
Primary outcome measure
The primary efficacy endpoint of the study will be VAS,
which is a pain score ranging from 0 mm (no pain) to
100 mm (worst pain ever experienced) [19], measured
during all the assessment visits (baseline and 1-, 2-, and
4-week follow-up). The VAS score is usually a horizontal
line, 100 mm in length, anchored by word descriptors at
each end. Patients mark the point of their current pain
on the line. The VAS score is then determined by meas-
uring in millimeters from the left end of the line to the
point that the patient marked.
Secondary outcome measure
The secondary efficacy endpoint of the study will be
rescue medication, WOMAC score [20] and micro-
perfusion alteration in the patellar fat pad, femur and
tibia subchondral bone.
Rescue medication complicates the interpretation of
trial results by having an effect on the trial outcome. It
is also possible to use rescue as a trial outcome. This is
common in trials of treatments for asthma, where use of
β2-agonists for rescue therapy may be a secondary trial
outcome [21]. Rescue medication in this trial is Ibupro-
fen, which is a short-term nonsteroidal anti-inflammatory
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with time in subjects in response to worsening of their
disease. Consumption and time the subjects use rescue
medication will be recorded in each randomized group.
The WOMAC score is a widely used proprietary set of
standardized questionnaires used by health professionals
to evaluate the condition of patients with osteoarthritis
of the knee and hip, including pain, stiffness, and phys-
ical functioning of the joints. The index measures five
items for pain (score range 0 to 20), two for stiffness
(score range 0 to 8), and 17 for physical function (score
range 0 to 68). It will be measured during all the assess-
ment visits (baseline and 1-, 2-, and 4-week follow-up).
To assess micro-perfusion alteration, two parameters
will be used: 1) maximum upslope represents the initial
uptake of gadolinium into the region measured by find-
ing the fastest uptake in the first few minutes after injec-
tion; 2) an enhanced rate represents the efflux rate
constant from the extravascular extracellular space to
plasma, which provides an index of venous hypertension
and represents the ratio of the permeability surface area
product over the extravascular extracellular space. With
the mean curve function, maximum upslope and en-
hanced rate in the distal femur and tibia plateau
subchondral regions of interest, and the infra-patellar fat
pad and supra-patellar fat pad regions of interest will be
measured and assessed.
Safety assessments
All subjects will be questioned about adverse events
during the treatment at each visit, and all adverse
events reported will be analyzed, regardless of the in-
vestigators’ assessments of causality. Safety will be
assessed by complete blood cell count, erythrocyte
sedimentation rate, blood chemistry, and urinalysis.
Randomization and blinding
Random assignment will be performed after consent is
obtained using a computer-generated, blocked random-
allocation sequence with a 1:1 ratio. The trial will be
blinded to both patients and assessor. We will designate
an independent researcher who is blinded to the inter-
ventions to be the assessor.
Sample size
Calculation of sample size is based on previous studies
assessing the efficacy and safety of Weishi Bitong Xifang
fumigation for mild and moderate KOA in patients [22].
Group sample sizes of 73 and 73 achieve 90% power to
detect a difference of 0.7 between the null hypothesis
that both group means are 30 mm (VAS score uses a
100-mm linear measure) and the alternative hypothesis
that the mean for the placebo group is 23 with estimated
group standard deviations of 12 and 13 and with asignificance level (alpha) of 0.05 using a two-sided test.
The number of patients actually provides less than 90%
power, assuming a withdrawal rate of 20%. Therefore,
we will recruit a total of 168 patients; 84 patients in each
group.
Statistical analysis
The data will be collected and analyzed according to the
intention-to-treat principle. We will compare baseline
characteristics in both groups. Efficacy analyses will be
performed for both the intent-to-treat population and
per-protocol population. The intent-to-treat population
will consist of all randomized subjects who have been
administered at least one treatment. In a per-protocol
analysis, only patients who complete the entire clinical
trial according to the protocol are counted in the final
results. Primary outcome will be compared between
both groups. The extent and time pattern of rescue
medication will be reported in each randomized group;
when comparing the underlying outcomes of the res-
cue medication, we assume the use of rescue medica-
tion varies with time, to allow for dependence within
patients, so we adopt a multilevel regression approach
with rescue as a time-dependent covariate [23]. Micro-
perfusion alteration outcome will be compared using
Student’s t-test. All statistical analyses will be performed
using SAS 9.2 software (SAS Institute Inc, Cary, NC,
USA). All statistical tests will be two-sided, and the level
of significance will be set at 0.05.
Discussion
This study will provide clinical evidence on the efficacy
of Jingui external lotion in treating KOA, and it will be
the first randomized controlled trial to investigate
micro-perfusion alteration of KOA with TCM external
lotion using a DCE MRI technique. In TCM, KOA
development is attributed to deficiency of the liver and
kidney, and deficiency of qi and blood, attack of wind-
cold-dampness evils, obstruction of channels and collat-
erals, qi and blood stagnation [24]. Thus, TCM that can
promote blood circulation, remove blood stasis, and ac-
tivate meridians to stop pain may be effective for KOA
[13]. Fumigation and washing of TCM has recently been
considered an inexpensive and convenient therapeutic
approach for KOA [25]. Jingui external lotion is a clas-
sical and well-known external therapy in the orthopedic
departments of TCM and has been demonstrated to
provide a satisfactory effect for KOA in the clinic. Well-
designed randomized controlled trials are needed to
examine the efficacy of TCM treatments for OA.
It has been revealed that Chinese medicine promoting
circulation and removing stasis could reduce intraoss-
eous pressure [26]. Intraosseous hypertension has been
reported to have an association with deep pain in
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dence to support the hypothesis that Chinese medicine
promotes circulation; therefore, we will employ a DCE
MRI technique to study micro-perfusion alteration, with
the aim of attaining objective evidence of Jingui external
lotion effectiveness in the treatment of patients with
KOA.
Trial status
Recruitment commenced in March 2014, and the trial is
scheduled to end in March 2016.
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